Invitris
New accelerator entry · 2023-03-10 · the record
In their words
Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.
What the record says
- One of 59 companies held here in Healthcare › Drug Discovery and Delivery.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Invitris
- Source Check — verify what Invitris states, against the registers that hold it.
- INVEST — size up this company on the figures its record states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Invitris for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist InvitrisYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Invitris: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.